GlaxoSmithKline Pharmaceuticals Limited (NSE: GLAXO)
India
· Delayed Price · Currency is INR | Market Cap | 383.72B |
| Revenue (ttm) | 35.60B |
| Net Income (ttm) | 6.75B |
| Shares Out | n/a |
| EPS (ttm) | 39.84 |
| PE Ratio | 56.85 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | Nov 7, 2024 |
| Volume | 45,267 |
| Open | 2,266.00 |
| Previous Close | 2,282.75 |
| Day's Range | 2,243.00 - 2,287.95 |
| 52-Week Range | 1,748.25 - 3,088.00 |
| Beta | 0.22 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Feb 10, 2025 |
About NSE: GLAXO
GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers vaccines, such as Infanrix Hexa for vaccination of infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and disease caused by Haemophilus influenzae type B; Synflorix for active immunization of infants against pneumococcal diseases and acute otitis media; Havrix for active immunization against disease caused by Hepatitis A virus; Menveo to prevent invasive meningococcal disease;... [Read more]
Financial Performance
In 2023, GLAXO's revenue was 34.54 billion, an increase of 6.21% compared to the previous year's 32.52 billion. Earnings were 5.90 billion, a decrease of -3.39%.
Financial StatementsNews
GSK Pharma sets record date for Rs 12 special interim dividend on November 7, 2024
GlaxoSmithKline Pharmaceuticals Limited (GSK Pharma) has announced the record date for its special interim dividend, set for November 7, 2024. This follows the company’s earlier declaration on October...